Your browser doesn't support javascript.
A Case of Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis Post COVID-19 Vaccination.
Al-Yafeai, Zaki; Horn, Benjamin Joesph M; Terraccaine, William; Jose, Alvin; Krishnan, Prathik.
  • Al-Yafeai Z; Internal Medicine, LSU (Louisiana State University) Health Shreveport, Shreveport, USA.
  • Horn BJM; Internal Medicine, LSU (Louisiana State University) Health Shreveport, Shreveport, USA.
  • Terraccaine W; Anaesthesia, LSU (Louisiana State University) Health Shreveport, Shreveport, USA.
  • Jose A; Emergency Medicine, LSU (Louisiana State University) Health Shreveport, Shreveport, USA.
  • Krishnan P; Pulmonary and Critical Care Medicine, LSU (Louisiana State University) Health Shreveport, Shreveport, USA.
Cureus ; 14(3): e23162, 2022 Mar.
Article in English | MEDLINE | ID: covidwho-1771731
ABSTRACT
In this report, we examine the case of a patient who developed antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis after receiving the Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine. This is a case of a 62-year-old female who received the first dose of COVID-19 vaccine in July 2021 before presenting a few weeks later with migrating polyarthralgia and hemoptysis. Autoimmune workup was positive for ANCA against proteinase 3 (PR3).
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report Topics: Long Covid / Vaccines Language: English Journal: Cureus Year: 2022 Document Type: Article Affiliation country: Cureus.23162

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report Topics: Long Covid / Vaccines Language: English Journal: Cureus Year: 2022 Document Type: Article Affiliation country: Cureus.23162